# Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
Canonical URL: https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-sy-df1f51d3
Ticker: BLTE
Company: Belite Bio
Source: Belite Bio
Published: 2026-07-06 12:00 EST
## Summary

Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company...

## Article Body
Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on Thursday, July 9, 2026, at 12:30 pm ET.

Webcast Link Instructions A webcast of the presentation can be accessed under "Events" in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events . The replay will be archived for 90 days following the presentation date.

About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X , Instagram , LinkedIn , and Facebook , or visit us at www.belitebio.com .

Media and Investor Relations Contacts: Jennifer Wu / ir@belitebio.com Argot Partners / belite@argotpartners.com
## Recent Company News
- 2026-07-20 12:00 EST — [Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1](https://biopharmsignal.com/news/BLTE/belite-bio-announces-oral-presentation-at-the-asrs-annual-meeting-featuring-addi-54caf9d6) — Source: Belite Bio
- 2026-07-15 12:00 EST — [Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference](https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-the-h-c-wainwright-6th-annual-ophthalmology-virtual-ac101a6e) — Source: Belite Bio
- 2026-07-06 12:00 EST — [Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium](https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-investor-sy-df1f51d3) — Source: Belite Bio
- 2026-07-06 11:00 EST — [Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences](https://biopharmsignal.com/news/BLTE/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-59165567) — Source: Belite Bio
- 2026-06-13 01:30 EST — [Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1](https://biopharmsignal.com/news/BLTE/belite-bio-completes-rolling-submission-of-new-drug-application-to-u-s-food-and--156ed1a0) — Source: Belite Bio
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)